Epinephrine auto-injector market research report
EARLY BIRD OFFER

Epinephrine Auto-Injector Market - Global Outlook and Forecast 2020-2025

PUBLISHED DATE : Apr 2020 | Pages : 233

Up to $1000 off Untill Oct 2020

EPINEPHRINE AUTO-INJECTOR MARKET SIZE TO CROSS USD 2 BILLION BY 2025, GROWING AT A CAGR OF 8% DURING THE FORECAST PERIOD

Epinephrine Auto-Injector Market Size, Share, & Trends Analysis Report by Dosage (High, Low), Age Group (Below 6 Years, Between 6 & 12 years, Above 12 years), End-user (Hospitals & Clinics, Individuals, Others), Geography (APAC, North America, Europe, Latin America, and Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2025.

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Customize this Report

Most Exhaustive Report

233 Pages

52 Tables

136 Charts

4 Regions

15 Countries

9 Companies

5 Market Segment

EPHINEPHRINE AUTO-INJECTOR MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 2 BILLION (2025)
CAGR 8% (2020-2025)
Base Year 2019
Forecast Year 2020-2025
Market Segments Dosage (High, Low), Age Group (Below 6 Years, Between 6 & 12 years, Above 12 years), End-user (Hospitals & Clinics, Individuals, Others)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered Argentina, Australia, Brazil, Canada, France, Germany, Israel, Japan, Netherlands, South Africa, South Korea, Spain, Turkey, UK, US

 MARKET DYNAMICS

The Epinephrine Auto-Injector Market Size to Cross USD 2 Billion By 2025, Growing at a CAGR Of 8%. The global epinephrine auto-injector market is expected to grow at a steady rate during the forecast period. The growth can be mainly attributed to the growing prevalence of anaphylaxis across demographics. Anaphylaxis is characterized as a potentially threatening systemic allergic reaction. It is most commonly triggered by medication, food allergies, or insect stings.

In US and the UK, the incidence of anaphylaxis is 40–500 per million persons, mortality is estimated at 0.63–0.76 per million. In the US, up to 5% population suffers from this condition. The clinical databases such as PubMed have captured the growing prevalence of anaphylaxis.

Globally, allergies caused by food items, food additives, latex, and dust are increasing at a steady rate. Such allergies, including anaphylaxis, are the most commonly prevalent in the US and the UK. Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of epinephrine as it the first-aid treatment option, thereby driving the global market.

SNIPPETS

  • The growing availability of generic epinephrine autoinjectors is one of the key drivers in the global market
  • North America is expected to witness an absolute growth of over 65% during the forecast period. The growth is due to the increase in the patient population and the wide availability of epinephrine auto-injectors
  • The high dose dosage segment is likely to observe an incremental growth of over $650 million. This growth is due to the high prevalence of anaphylaxis in teenage and adult patient groups
  • The above 12 years segment is expected to grow at a double-digit growth rate during the forecast period
  • The individuals’ end-user segment is projected to grow at a CAGR of over 9% during the period 2019–2025. The growth is on account of self-management of anaphylaxis through epinephrine auto-injectors

EPINEPHRINE AUTO-INJECTOR MARKET SEGMENTATION

This research report includes a detailed segmentation by 

  • dosage
  • age group
  • end-user
  • geography

INSIGHTS BY DOSAGE

The growing incidence of anaphylaxis in the adults & elderly is the primary factor driving the growth of the high dose segment. Epinephrine is considered as the first-line treatment for anaphylaxis. The increasing recommendation of high dose for adult patients is fueling the growth of the segment. Moreover, market players are also focusing on providing generic, low-cost products. This is increasing the demand for affordable treatment options for managing anaphylactic reactions.

The prevalence of food allergies is estimated to be high in children. Several studies have shown the majority of food allergy incidences, including anaphylaxis, occurs in schools or daycare centers. The National Institute of Allergy and Infectious Diseases guidelines recommend epinephrine as a first-line treatment option. Therefore, epinephrine auto-injectors are considered as an integral part of emergency care in schools and daycare centers.

The increasing prevalence of anaphylaxis in children is the key driver for the growth of the low dose segment. Further, the increasing commercialization of epinephrine auto-injectors for infants in the US and the approval of generic versions by the FDA are driving the growth of low dose segment market.

INSIGHTS BY AGE GROUP 

Several social and emotional factors contribute to the high prevalence of anaphylaxis in teenage and adult groups. Adults with peanut allergy have more severe reactions than children. HCPs recommend a safe dose (usually 0.3 mg) of epinephrine auto-injectors to the patient group aged 12 years and above.

Anaphylaxis in the elderly population tends to be threatening and requires intensified medical intervention. Therefore, managing the high risk of anaphylaxis in elderly people is expected to drive the uptake of epinephrine auto-injectors.

The burden of anaphylaxis among children is growing, hence it requires quick and effective management. Government and regulatory bodies are providing safeguards to prevent fatal reactions among children in the 6–12 years age group. Epinephrine through auto-injectors acts fast and can rapidly treat the most dangerous symptoms in children. Thus, it is always been recommended to make ready epinephrine auto-injectors for children in schools to avoid fatal conditions. Therefore, this is driving the segment growth.

In 2019, the below 6 years segment accounted for a 10% share of the global epinephrine auto-injector market. Children in this age group are prescribed to be treated with 0.15 mg/0.1 mg dose capacity.

An estimated 130% increase in emergency room visits for anaphylaxis among children reported between 2005 and 2014. The management of anaphylaxis in this age group is becoming a major concern among HCPs and parents. Vendors are focusing on introducing low-cost epinephrine auto-injectors for this age group.

INSIGHTS BY END-USER

The individual end-user segment accounted for the highest share and growth rate in 2019. This is mainly due to the growing demand for self-management of anaphylaxis. Individuals carry epinephrine auto-injectors for the treatment of sudden anaphylaxis shock. Hence, the segment is likely to emerge as a major revenue generator during the forecast period.

HCPs in hospitals & clinics are using epinephrine auto-injectors for the emergency management of anaphylaxis. The market is growing at a healthy rate. It is due to the high adoption of autoinjector devices by emergency departments in hospitals and clinics. The availability of skilled HCPs with knowledge and expertise also attracts many patients to hospitals and clinics.

Large and medium-sized hospitals are equipped with sophisticated healthcare infrastructure for emergency management of anaphylaxis. Hence, the share of this segment is likely to grow at a steady growth during the forecast period.

INSIGHTS BY GEOGRAPHY

North America dominates the epinephrine auto-injector market. The presence of a large disease population, coupled with better access to treatment for anaphylaxis, is the primary factor for its high market share. The strong presence of key players is also another reason for high product uptake in the region. Moreover, the rise in the anaphylactic patient pool and the launch of generic substitutes, which help to treat the condition effectively in adults and children groups, are likely to boost the growth during the forecast period.

Europe is the second-largest market. Better disease awareness, high healthcare spending, and the presence of key vendors are the primary factors for high shares. Germany, France, the UK, Spain, and the Netherlands are the major revenue contributors to the region. The Europe region is likely to be driven by the increasing treatment-seeking population due to increased awareness of anaphylactic reactions.

Japan, Australia, and South Korea are the major revenue contributors in APAC for epinephrine auto-injectors.

INSIGHTS BY VENDORS

The global epinephrine auto-injector market is highly consolidated. It is characterized by the presence of a few established vendors holding the majority of the shares. Vendors are offering several branded as well as generic epinephrine auto-injectors and are competing based on factors in terms of regulatory approvals, safety features, accurate dosing, convenience, technology, marketing strategies, and distribution channels.

Teva Pharmaceutical Industries offers generic version of Mylan’s EpiPen and EpiPen Jr to treat life- threatening anaphylaxis allergic reactions. Alk-Abello's epinephrine auto-injectors product line includes Jext 0.3 mg and 0.15 mg. The product gained wide popularity for the emergency treatment of anaphylactic shock.

The Epinephrine auto-injector research report includes in-depth coverage of the industry with growth rates, revenues & forecasts for the following segments:

Market Segmentation by Dosage  

  • High
  • Low

By Age Group 

  • Below 6 Years
  • Between 6 & 12 years
  • Above 12 years

By End-user  

  • Hospitals & Clinics
  • Individuals
  • Others

By Geography

  • Europe
    • Spain
    • Germany
    • Netherlands
    • France
    • UK
  • North America
    • US
    • Canada
  • APAC
    • South Korea
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • Turkey
    • Israel
    • South Africa

Frequently Asked Questions

The global epinephrine auto-injector market size to cross $2 billion by 2025, growing at a CAGR of over 8% during the forecast period.
Mylan, Teva Pharmaceutical Industries, Amneal Pharmaceuticals are the leading vendors in the market.
North America dominates the epinephrine auto-injector market. Europe is the second-largest market.
The following factors are likely to contribute to the growth of the epinephrine auto-injector market during the forecast period: Emergence of Innovative Solutions for Anaphylaxis Management Increasing Demand for Generic Epinephrine Auto-injectors at Pharma/Retail Stores Growing Demand for Self-administration of Drugs Availability of Generic Versions of Auto-injectors
Read More

Select a license type that suits your business needs

Single User Licence
$2800.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$3200.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$4000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$1600.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Select a license type that suits your business needs

Best Value Tag
Coming Soon
  • Stay tuned with us.

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

Our Clients

20%

Off

FLASH DISCOUNT

DAYS

HOURS

MINUTES

SECONDS

Prebook Tag
Licence Types What are these?
10 % OFF

on buying this report before the release date

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date